Arbutus Biopharma Corp. Company Profile (NASDAQ:ABUS)

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corp. (NASDAQ:ABUS) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $11.95 (191.46% upside)

Analysts' Ratings History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016WedbushReiterated RatingOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2016Chardan CapitalDowngradeNeutral -> Sell$3.25 -> $2.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015Royal Bank Of CanadaLower Price Target$20.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015JMP SecuritiesInitiated CoverageOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015Nomura Holdings Inc.Initiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Stifel NicolausReiterated RatingPositive -> Buy$31.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Clarus SecuritiesInitiated CoverageBuy$22.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.39)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q4($0.41)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.31)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015($0.32)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.31)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.26)($0.28)$3.72 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corp. (NASDAQ:ABUS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.36)($0.37)
Q2 20162($0.40)($0.35)($0.38)
Q3 20162($0.41)($0.39)($0.40)
Q4 20162($0.39)($0.36)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arbutus Biopharma Corp. (NASDAQ:ABUS)
DateHeadline
07/22/16 10:25 AMArbutus Biopharma Corp (NASDAQ:ABUS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 02:15 PMEquity Roundup: Stock Performance Focus on Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph
07/21/16 10:29 AMBroker Outlook For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard
07/20/16 10:24 AMEarnings Focus and Crowd Sourced Sentiment Review for Arbutus Biopharma Corp (NASDAQ:ABUS) - TGP
07/20/16 10:24 AMArbutus Biopharma (ABUS) Says TKM-PLK1 Well-Tolerated in Phase I/II Trial - StreetInsider.com
07/19/16 07:42 PMArbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial
07/16/16 02:15 PMArbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 8.15% - Consumer Eagle
07/15/16 06:30 PMAnalyst Target and Average Rating Watch: Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph
07/15/16 06:30 PMArbutus Biopharma Corp (NASDAQ:ABUS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 07:44 PMTrading Performance and Target Watch for Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph
07/14/16 06:20 PMAndreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech -
07/14/16 02:15 PMChardan Capital Downgrades Arbutus Biopharma Corp to Sell - TheFounders Daily
07/14/16 02:15 PMArbutus Biopharma Corporation Realized Volatility Hits Extreme Level - CML News
07/13/16 03:01 PMRoivant Sciences Appoints Professor Andrew Lo, PhD as Independent Director - [PR Newswire] - HAMILTON, Bermuda, July 13, 2016 /PRNewswire/ -- Roivant Sciences Ltd. ("Roivant"), a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the ...
07/12/16 07:44 PMArbutus Biopharma Corp (NASDAQ:ABUS) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/11/16 07:02 AMStock Rating Watch and Earnings Insight for Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph
07/10/16 02:15 PMArbutus Biopharma Corporation (NASDAQ:ABUS) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 10:22 AMArbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Covered 8.15% of Their Shorts - Press Telegraph
07/08/16 02:16 PMCompany Stock Focus for Arbutus Biopharma Corp (NASDAQ:ABUS): Which Way Will Shares Head? - Press Telegraph
07/07/16 02:15 PMArbutus Biopharma Corporation Stock Momentum at Critical Inflection Point - CML News
07/06/16 07:02 AMArbutus Biopharma Corp (NASDAQ:ABUS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/05/16 07:02 AMEye Catching Stocks: Arbutus Biopharma Corporation (NASDAQ:ABUS), Facebook Inc (NASDAQ:FB), Organovo ... - KC Register
07/04/16 02:15 PMDoes Arbutus Biopharma Corp Have Any Gas After Today's Huge Increase? - Press Telegraph
07/01/16 07:29 PMArbutus Biopharma Corp (NASDAQ:ABUS) Earnings Glance and Target Price Review - Engelwood Daily
07/01/16 07:29 PMCovering the Bases on Arbutus Biopharma Corp (NASDAQ:ABUS): Where is the Stock Going? - Press Telegraph
07/01/16 02:15 PMArbutus Biopharma Corporation (NASDAQ:ABUS) Updated Price Targets - FTSE News
06/30/16 02:15 PMTekmira Pharmaceuticals Corporation: Arbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the ... - The Wall Street Transcript
06/30/16 07:01 AMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Other Events -
06/30/16 07:00 AMArbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the Japan Society of Drug Delivery System - [GlobeNewswire] - In Vivo Data Support Use of Our Proprietary LNP Platform Technology Arbutus Has a Dominant IP Position in LNP-Enabled Delivery. VANCOUVER, British Columbia and DOYLESTOWN, Pa., June 30, 2016-- Arbutus ...
06/29/16 02:14 PMRecently Issued Stock Ratings For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard
06/29/16 10:10 AMArbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Covered 8.15% of Their Shorts - Engelwood Daily
06/25/16 10:19 AMChardan Capital Upgrades Arbutus Biopharma Corp to Neutral with Price Target $3.25 - TheFounders Daily
06/24/16 10:12 AMNew Broker Ratings For Arbutus Biopharma Corporation (NASDAQ:ABUS) - FTSE News
06/20/16 02:15 PMThis Weeks Broker Views For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard
06/08/16 11:20 AMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/01/16 07:03 AMArbutus to Present at the 5th Antiviral Drugs Research and Development Conference - [at noodls] - June 1, 2016 First In Vivo Data from Arbutus HBV Preclinical Combination Studies Additive Anti-HBV Effects When Combining Capsid Inhibitor AB-423 with Current Standard of Care VANCOUVER, British Columbia ...
05/28/16 10:37 AMIs Selling Stock Like Arbutus Biopharma Corp After Such Decline Winning Strategy? - HNN - Is Selling Stock Like Arbutus Biopharma Corp After Such Decline Winning Strategy?HNNThe stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! The stock decreased 3.76% or $0.16 on May 27, hitting $4.1. About 68,004 shares traded hands. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 29.07% since October ...
05/25/16 01:09 PMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 12:44 PMArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 06:39 AMCoverage initiated on Arbutus Biopharma by Chardan Capital Markets -
05/12/16 12:04 PMARBUTUS BIOPHARMA CORP Financials -
05/04/16 08:15 PMEdited Transcript of ABUS earnings conference call or presentation 4-May-16 8:30pm GMT -
05/04/16 03:54 PMArbutus reports 1Q loss -
05/04/16 03:10 PMArbutus Provides Corporate Update and Announces First Quarter 2016 Financial Results - [at noodls] - May 4, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...
05/04/16 03:05 PMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex -
05/04/16 12:08 PMQ1 Conference Call: Arbutus Biopharma Corp (NASDAQ:ABUS) - share market updates (press release) - share market updates (press release)Q1 Conference Call: Arbutus Biopharma Corp (NASDAQ:ABUS)share market updates (press release)Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) ended Tuesday session in red amid volatile trading. The shares closed down -0.13 points or -2.70% at $4.69 with 140,808.00 shares getting traded. Post opening the session at $4.75, the shares hit an ...Arbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 6.97%B.O.D.Y Confidentialall 3 news articles »
05/04/16 06:07 AMQ1 2016 Arbutus Biopharma Corp Earnings Release - Time Not Supplied -
05/03/16 03:40 PMArbutus Expands HBV Pipeline - [at noodls] - May 3, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions ...
05/02/16 01:23 PMTekmira Pharmaceuticals Corporation: Arbutus to Provide a Corporate Update and Release First Quarter 2016 ... - The Wall Street Transcript - Tekmira Pharmaceuticals Corporation: Arbutus to Provide a Corporate Update and Release First Quarter 2016 ...The Wall Street TranscriptVANCOUVER, British Columbia and DOYLESTOWN, Pa., April 29, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a ...Arbutus Biopharma Corporation (ABUS) Updated Broker Price TargetsShare Trading Newsall 2 news articles »
04/29/16 07:18 AMArbutus to Provide a Corporate Update and Release First Quarter 2016 Financial Results - [at noodls] - April 29, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 29, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...

Social

About Arbutus Biopharma Corp.

Arbutus Biopharma Corp. logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABUS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.10
  • 50 Day Moving Average: $3.75
  • 200 Day Moving Average: $3.91
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $223.96M
  • Beta: 1.24
  • Current Year EPS Consensus Estimate: $-1.46 EPS
  • Next Year EPS Consensus Estimate: $-1.48 EPS
Additional Links:
Arbutus Biopharma Corp. (NASDAQ:ABUS) Chart for Wednesday, July, 27, 2016